Podcasts about Lysis

“‘Shall we assume, then, that … the bad is akin to the bad; the good to the good; and what is neither good nor bad to what is neither good nor bad?'They said they thought it was so: each was akin to its counterpart.‘In that case, boys,' I said, ‘haven't we fallen back into those first statements of ours about friendship, which we rejected, since one unjust man will be a friend to another unjust man, a bad man to another bad man, no less than one good man to another good man?'‘It would appear so,' they said. …‘Then I don't know what more to say.'With that I was intending to provoke another of the older men into speaking. Just then, like evil spirits, Lysis's and Menexenus's tutors came over with the boys' brothers, called to them, and told them to come home; it was already late. …However, I did say, just as they were leaving, ‘Lysis and Menexenus, we've now made utter fools of ourselves, an old man like me and you, since these people will go away and say that we think that we're friends of one another – for I consider myself one of your number – though we were not as yet able to find out precisely what a friend is.'”(Lysis, 222c-223b) Get full access to The Philosophy Garden: Stoicism and Beyond at thephilosophygarden.substack.com/subscribe

“‘All right then,' I said. ‘Now that we've got as far as this, boys, let's be careful not to be deceived.' …‘Let's consider the following case: medicine, we say, is a friend for the sake of health.'‘Yes.'‘Is health a friend too, then?'‘Of course.'‘If it is a friend, it is so for the sake of something.'‘Yes.'‘And that something is a friend, if it is to be consistent with what we admitted earlier.'‘Of course.'‘And that too, in its turn, will be a friend for the sake of a friend?'‘Yes.'‘Well then, aren't we bound to get tired going on like that and give up, or else arrive at some point of origin which will not refer us to yet another friend, but which will constitute the first thing that is a friend, for the sake of which we say that all the others too are friends?'‘We are.' …“Admittedly, we do often say that we value gold and silver highly, but that hardly comes any nearer the truth. What we value most highly is that thing (whatever it may reveal itself as being) for the sake of which both gold and everything else that is procured are procured. Shall we settle for that?'‘Of course.'”(Lysis, 219c-220a)The Philosophy Garden: Stoicism and Beyond is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thephilosophygarden.substack.com/subscribe

“‘That's why we'd say that those who are already wise, whether they are gods or men, no longer love wisdom, and that those who are so ignorant that they are bad do not love wisdom either, because no bad or stupid man loves wisdom.So, we're left with those who possess that bad thing, ignorance, but have not yet been rendered foolish or stupid by it, in that they still believe they don't know what they don't know.Consequently those who are still neither good nor bad do, in fact, love wisdom; whereas all those who are bad, as well as all those who are good, do not, because, as we decided earlier in our discussion, neither is opposite the friend of opposite, nor like of like. Don't your remember?'‘Of course,' they said.‘So now, Lysis and Menexenus,' I said, ‘we've done it! We've discovered what a friend is and what it is not. We say that in the soul, in the body and anywhere else, it is what is neither bad nor good that is the friend of the good because of the presence of bad.'The two of them agreed wholeheartedly, admitting that it was so.”(Lysis, 218a-218c)The Philosophy Garden: Stoicism and Beyond is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thephilosophygarden.substack.com/subscribe

“‘Have you come across the writings of our wisest men, which say that like must always be friend to like? These are, of course, the men who discuss and write about nature and the universe.'‘That's true,' he said.‘Well,' I said, ‘are they right?'‘Possibly,' he replied. …[But] ‘We think that the closer one wicked man gets to another wicked man and the more he associates with him, the more he becomes hated by him, because he wrongs him; and it is, of course, impossible for wronger and wronged to be friends, isn't it?'‘Yes,' he replied. …‘Well then, in my opinion, Lysis, this is what people mean when they say, in their cryptic way, that like is friend to like: friendship exists only between good men, whereas the bad man never achieves true friendship with either a good or a bad man. Do you agree?'He nodded assent.”(Lysis, 214b-214d)The Philosophy Garden: Stoicism and Beyond is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thephilosophygarden.substack.com/subscribe

“Ever since I was a boy I've always desired to acquire a certain thing. You know how different people desire different things: for example one man desires to acquire horses; another, to acquire dogs; another, gold; another, honors. I'm quite indifferent to those things, but I do passionately love acquiring friends. I'd rather get a good friend than the best quail or cock in the world. …When I see you two, you and Lysis, I'm amazed, and think you must be very happy because, though you are so young, you've been able to acquire that possession quickly and easily: you've acquired Lysis as a friend so quickly and firmly; and he, you. Whereas I'm so far from acquiring one that I don't even know how one man becomes the friend of another. That's what I want to ask you about, in view of your experience.Tell me, when a man loves someone, which is the friend of which? Is it the one who loves who is the friend of the one who is loved? Or is it the one who is loved who is the friend of the one who loves? Or is there no difference?[After a spirited back and forth, Socrates concludes:]Then, Menexenus, it would appear that what is loved is dear to what loves it whether it loves what loves it or whether it actually hates it. For example, some newly born children do not yet love, while others actually hate their mother or father when they are punished by them. None the less they are most dear to their parents at the time they actually hate them. …That will mean, then, that we must allow exactly what we allowed earlier in our discussion, that a man is often the friend of what is not his friend, and often of what is actually his enemy, when he either loves what doesn't love him, or loves what actually hates him; and that a man is often the enemy of what is not his enemy, or of what is actually his friend, when he either hates what does not hate him, or hates what actually loves him. …‘Heavens, Socrates,' he said, ‘I don't know what to say.'Can it be that we were not conducting our investigation properly at all, Menexenus?, I asked.”(Lysis, 211d-213d)The Philosophy Garden: Stoicism and Beyond is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thephilosophygarden.substack.com/subscribe

Tällä kertaa Mikä on tärkeää? -podcastin jaksossa keskustellaan Kauppalehden vuotuisesta "Miten toimistoilla menee?"-artikkelista (ajasta 1:32 alkaen), tekoälysisällön tunnistamisen merkityksestä journalismissa vs. markkinoinnissa (15:52) sekä kuluttajien mielipiteistä Black Fridaystä (28:44). Tällä kertaa juontaja Santtu Kottilan ohella panelisteina Sanoma Content Studion vetäjä Tapio Haaja ja Tricklen Suomen maajohtaja Laura Myllykoski. Linkit podcastissa nostettuihin artikkeleihin: 1)https://www.kauppalehti.fi/uutiset/tassa-ovat-suomen-50-suurinta-markkinointitoimistoa-katso-kln-lista-voittajista-ja-haviajista/f1e41ad3-63c0-4ee4-b38d-367ee537d82e 2)https://www.markkinointiuutiset.fi/artikkelit/yle-perustaa-uuden-tiedon-varmentamiseen-erikoistuvan-tiimin 3)https://www.markkinointiuutiset.fi/artikkelit/suomalaisten-black-friday--budjetti-pienentynyt-kymmenisen-prosenttia ***** Mikä on tärkeää? -podcast on MarkkinointiRadion ohjelma, jossa kammataan läpi ajankohtaisia ja jokaiselle markkinoijalle tärkeitä uutisia. Mukana on viiden panelistin joukko, joista kaksi on kerrallaan ohjelman juontaja Santtu Kottilan vieraana. Jokainen panelisti tuo Kottilan lisäksi mukanaan ajankohtaisen ja merkittävän uutisen tai ilmiön, minkä tärkeyden ja merkityksen raati käsittelee. Joka viikko käydään siis läpi kolme tärkeää ja ajankohtaista aihetta. Lisätetoja Mikä on tärkeää? -podcastista saat esimerkiksi täältä: www.mkollektiivi.fi/mika-on-tarkeaa Podcast toteutetaan yhteistyössä tietoliikenneyhtiö Telia Finlandin, strategisen bränditoimisto Wörksin, digimarkkinointitoimisto Tricklen sekä strategisen sisältötoimisto Sanoma Content Studion kanssa.

“I put my questions to Lysis: ‘I suppose, Lysis, your father and mother love you very much?'‘Of course,' he replied.‘Then they'd want you to be as happy as possible?'‘Naturally.'‘Do you think that a man is happy when he's a slave and allowed to do nothing he desires?'‘Heavens, no, I don't,' he said.‘Then if your father and mother love you and desire your happiness, it's absolutely clear that they must do their best to make you happy.'‘Of course,' he said.‘So they let you do what you want and don't scold you at all or stop you doing what you desire?'‘Heavens, no, Socrates, there are lots and lots of things they stop me doing.'…‘So your father deliberately sets lots and lots of bosses and masters over you. But when you go home to your mother, she lets you do what you want with her wool or her loom when she's weaving, so that she can see you perfectly content.'Lysis laughed and said, ‘Heavens, Socrates, not only does she stop me, but I'd actually be beaten if I touched any of that.'…‘Well then, what have you done to make them behave so oddly and stop you being happy and doing what you want, and bring you up by keeping you all day long in a state of constant subjection to someone else and in short doing virtually nothing you desire.'…‘It's because I'm not yet of age, Socrates,' he said.‘I'm not sure it's that that stops you, Lysis, since both your father, Democrates, and your mother trust you to some extent, I imagine, without waiting until you're of age. For example, when they want things read to them or written for them, I imagine they give that job to you before anyone else in the house. Don't they?'‘Of course,' he replied.…‘So, Lysis, what on earth can be the reason for their not stopping you in those cases, whereas they do stop you in the ones we were speaking of just now?'‘I suppose it's because I know about those things but not the others,' he replied.‘Well,' I said. ‘Excellent! So your father is not waiting for you to come of age to trust everything to you, but on the day he considers that you know better than himself, he'll trust both himself and his property to you.'‘I expect so,' he said.”(Lysis, 207d-209d)The Philosophy Garden, Stoicism and beyond is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thephilosophygarden.substack.com/subscribe

Matters Microbial #62: Should I Stay, or Should I Go—How Bacteriophage are Released from Host Cells October 23, 2024 Today, Dr. Jolene Ramsey, of the Biology Department of Texas A&M University and Affiliate of the Center for Phage Technology, joins the #QualityQuorum to discuss how bacteriophages release themselves from host cells, her efforts to teach students to work with the primary literature, and her own path to the microbial sciences.   Host: Mark O. Martin Guest: Jolene Ramsey Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A truly wonderful reminder video about bacteriophages. A link with a 3D printer design of capsid model pieces (personally, I am really interested in making one of these!). A video demonstrating how the capsid model pieces self assemble—something like real viruses can? An essential book about bacteriophage authored by my late friend Merry Youle. A fine book describing how bacteriophages can be used to fight bacterial diseases. This “first person” book by #MattersMicrobial podcast guest Steffanie Strathdee about how she was able to use bacteriophages to save her husband's life is a must read. A link to the Citizen's Phage Library. A link to the truly fabulous (yes, I am jealous I am not part of this program) CURE program SEA-PHAGES and SEA-GENES for undergraduate students. A remarkable illustration of T4 bacteriophage bursting from host cells by the scientist-artist David Goodsell. The organization that designed Dr. Ramsey's laboratory logo. A link to the Clinical Genome Curation for Human Genes.   A link to the CACAO website for biocuration competition. A recent Ramsey lab mini-review on phage classification. A link to the Center for Phage Technology. The Ramsey lab Instagram page. The Ramsey lab YouTube channel. Dr. Ramsey's laboratory website. Dr. Ramsey's faculty website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

While some of us knew a good bit about mRNA prior to 2020, we all got a crash course on mRNA technology and its prophylactic and therapeutic potential as a result of the COVID pandemic and subsequent SARS CoV-2 vaccine development. In fact, most of us have now received at least one mRNA vaccine at this point. Our guest for this episode, Dr. Christian Cobaugh, Co-founder and CEO of Vernal Biosciences, was a passionate believer in mRNA medicines well before the pandemic. Join us to hear his story and his passion for this technology. He walks us through the molecular methods by which high-purity mRNAs are now made and purified, as well as going into the lipid nanoparticle technology by which they're commonly delivered. As a contract development and manufacturing provider, we get to learn about the state of the market and what clients of their care about today. As a seasoned expert in this space, Christian talks about the future potential of mRNA technology for applications such as personalized cancer vaccines. If you enjoy hearing smart people talk about interesting topics with a passion, you won't want to miss this episode! Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Download Transcripts: Speaking of Mol Bio Podcast | Thermo Fisher Scientific - US Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology.

Joining Sean Defoe in for Anton, to discuss the main stories in the Sunday papers was Aoife Barry Freelance journalist and author, John Cunningham Relationship director, Morgan Mckinley Chair and country director Lysis group and Gabija Gataveckaite Political Correspondent with the Irish Independent

Joining Anton to review the main stories in the Sunday papers are Saoirse McHugh, Independent candidate for the Midlands-North-West, Gary Murphy, Professor of Politics at DCU, John Cunningham, Relationship director, Morgan Mckinley, Chair and country director Lysis group.

Did you know that the treatments used to cure pediatric cancers can potentially cause a life-threatening event known as tumor lysis syndrome (TLS)? Arfa Ul-Haque and Yazmin Reategui, two third-year medical students, are joined by Pediatric intensivist, Dr. Smitha Mathew, to discuss the evaluation and management for TLS so that it is promptly recognized and treated in the inpatient hospital setting.   Specifically, they will:  Review the basic assessment skills and evaluation for a child presenting with potential TLS   Discuss the influence of chemotherapy, initial presentation, diagnostic options, and management of electrolyte imbalances found in TLS  Medications reviewed: daunorubicin, cytarabine, calcium gluconate, Rasburicase, allopurinol  Anticipatory guidance to medical professionals for potential onset of TLS  Special thanks to Dr. Eric Ring and Dr. Rebecca Yang for peer reviewing this episode. References: Tumor lysis syndrome. (2022, October 4). Medscape.com. https://emedicine.medscape.com/article/282171-overview Adeyinka A, Bashir K. Tumor Lysis Syndrome. [Updated 2022 Oct 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518985/ Cheung WL, Hon KL, Fung CM, Leung AKC. Tumor lysis syndrome in childhood malignancies. Drugs in Context 2020; 9: 2019-8-2. DOI: 10.7573/dic.2019-8-2 Cheung, Ho Hung MBBSa; She, Wong Hoi MBBSa,∗; Yap, Desmond Y.H. MDb; Tsang, Simon H.Y. MBChBa; Cheung, Tan To MDc. A case report of tumor lysis syndrome after stage-one ALPPS. Medicine 101(10):p e29040, March 11, 2022. | DOI: 10.1097/MD.0000000000029040 Flood, K., Rozmus, J., Skippen, P., Matsell, D. G., & Mammen, C. (2021). Fluid overload and acute kidney injury in children with tumor lysis syndrome. Pediatric Blood & Cancer, 68(12), e29255. https://doi.org/10.1002/pbc.29255 Barbar T, Jaffer Sathick I. Tumor Lysis Syndrome. Adv Chronic Kidney Dis. 2021 Sep;28(5):438-446.e1. doi: 10.1053/j.ackd.2021.09.007. PMID: 35190110. Adeyinka A, Bashir K. Tumor Lysis Syndrome. [Updated 2022 Oct 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518985/ Shenoy MT, D'Souza B, Akshatha LN, D'Souza V, Rajan MG. Spontaneous Tumor Lysis Syndrome in an Infant: A Case Report. Indian J Clin Biochem. 2015 Jul;30(3):360-2. doi: 10.1007/s12291-014-0472-y. Epub 2015 Feb 14. PMID: 26089626; PMCID: PMC4469048. Alakel N, Middeke JM, Schetelig J, Bornhäuser M. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther. 2017 Feb 2;10:597-605. doi: 10.2147/OTT.S103864. PMID: 28203093; PMCID: PMC5295804. Kollathodi SB, Parameswaran KK, Madhavan L, Kuruvilla S. Hematological malignancies presenting as spontaneous tumor lysis syndrome: A case series. J Family Med Prim Care. 2018 Sep-Oct;7(5):1116-1119. doi: 10.4103/jfmpc.jfmpc_171_18. PMID: 30598972; PMCID: PMC6259502.    

Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.

On this episode of The Founder's Sandbox, Brenda speaks with Oscar Neyra, CEO and founder of Lisus Energy, about building a sustainable business model. Lisus  is focused on identifying better sites to source materials for batteries. Oscar holds a Doctorate in Environmental Science and Engineering from UCLA, as well as a Master studies in Homeland Security from USC and Global Security from John Hopkins. Before starting LISUS, Oscar was a Research Associate at NASA's Jet Propulsion Laboratory. He also founded an environmentalist group called GR, which has over 5,000 members. Here is a sample of what you will hear in this episode: types of teams in deep tech, challenges of entrepreneurship in the current enviroment and as an immigrant founder, and product market fit. To contact this week's guest,  Oscar Neyra,  or for more information follow the links below:  partnerships@lisus.com www.lisusenergy.com https://www.linkedin.com/in/oneyran/ Resources listed in this episode: Gene Pool Engineering for Entrepreneurs https://www.khoslaventures.com/gene-pool-engineering-for-entrepreneurs/ https://www.Rabbit.tech https://nextactadvisors.com/when-spending-time-in-the-sandbox-isnt-fun-anymore-and-yet-you-still-can-play/ Show transcript: 00:04 Welcome back to the Founders Sandbox. The Founders Sandbox is a monthly podcast. I'm Brenda McCabe, your host. This was launched in September 2022. We're into our second season. And as I said, it's a monthly podcast.   00:33 that features entrepreneurs and business owners who learn and share about building resilient, scalable and sustainable businesses, all with great corporate governance. I have a very simple mission with this podcast. I want to assist the entrepreneurs and entrepreneurs to build scalable well governing resilient businesses. The podcast, the Founder Sandbox, is just an additional channel to   01:02 materials on my website, NextAct Advisors, and originally authored blog posts that you can find on LinkedIn. My guests are founders, business owners, corporate directors, and professional service firms who, like me, want to use the power of the enterprise, be it small, medium, or large, to create change for a better world. Through storytelling, each of my guests touches topics around resilience, purpose-driven enterprises, and sustainable growth. And my goal with this   01:31 monthly podcast is actually to equip one startup founder at a time to build a better world through great corporate governance. So today my guest is Oscar Neyra. Oscar is the CEO of Lisus, a venture-backed startup that is focusing on identifying better sites to source materials for batteries. And when I spoke with Oscar, we came up with the episode title   02:00 a sustainable business model and a sustainable market. So Oscar, thank you for joining me here in the Founder's Sandbox. Thank you so much, Brenda. It's my pleasure to be here. Let me give you some intro. Oskar holds a doctorate in environmental science and engineering from UCLA, as well as a master's studies in homeland security from USC and global security from Johns Hopkins. Before starting Lisus, Oskar was a research associate   02:28 at NASA's Jet Propulsion Laboratory. And he also founded an environmental group called GR, which has over 5,000 members. Oscar, my past that crossed at USC Viterbi Engineering Schools, Massey Entrepreneurship Prize Competition. About three years back, I was one of the judges on the panel in the pitch session. About a year later, Oscar asked me to join his advisor.   02:58 in corporate governance in lisus. And I'm sharing that here in my podcast as a full disclosure. And we have, we see each other frequently. And I thought as a first time founder with really deep technical and scientific knowledge and into your third year, you have a lot of stories that you could share here on the podcast. And I'm going to ask you, you know, I'm delighted you joined, but I'm going to ask you to start.   03:27 Just, you know, share how your life up till now, Oscar, has shaped your journey in entrepreneurship. Thank you so much, Brenda. Yeah, I think definitely entrepreneurship is a really interesting endeavor. You know, I don't come from a wealthy background. I come from a small town in Mexico. And all my life, I've been used to navigating against the current.   03:56 probably being the first member of my family to come to the US to study or to go to grad school. So I think entrepreneurship and this adventure resonates a lot with the path I've had in my life because it's a lot about being persistent and definitely going against the current and against   04:23 all the challenges that entrepreneurs like me face on a daily basis. Wow, thank you. It's always good to know the background of my guests. When you accepted to join me in the Founder Sandbox, I couldn't help. And you're technical scientists, right? PhD. Yeah, it took me back to an article I wrote some time back. It's called, When Spending Time in the Sandbox Isn't Fun Anymore.   04:52 and yet you can still play. So what I wrote is really about the teams. There are three types that I have discovered when working with technical founders. And we're gonna cut to the chase. I'm gonna ask Oscar in a minute what his perfect team is like. But in that blog post, I talk about technical scientific founding teams. Typically they come from a large enterprise. They excel at their craft as engineers, inventors. They have written patents, have worked at the bench for years.   05:22 And while their secret sauce has become a business, they don't have the skills and competencies in a technical or scientific founding team. They're insufficient to scale the business and they need time away from the sandbox and really working on the commercialization. And the second type of team is they've been there and done it. Founding teams, maybe it's their first or second exit. They've been there and done that. They may have the skills and competencies acquired at a large enterprise.   05:52 or a family-owned business, maybe they've been part of a startup, or they are bringing to life the idea of a patented product. Again, we're talking about scientific founders. And time in the sandbox, we're always gonna go back to the sandbox, was never an issue because they had access to abundant resources. Finally, a third type of team that I've been exposed to is the adult supervision.   06:16 And they are founders that have never worked for a large or medium sized enterprise with the processes, systems and operations that enable scaling a company. They've never hired or fired and they're many first. And they look around, say, isn't there an adult around that can help, can take the time to do those unnecessary things. So Oscar, of those three teams, you know, where would you place the licensed teams? And more importantly, you know, what does a perfect team?   06:47 mean to you and how have you, what makes a perfect team? Perfect, yeah. To the first question, I would say we're probably in the first definition, which is we come right from the lab. And before founding a startup, we definitely didn't know what was going to be. And of course, what are some of the things that you need to do?   07:15 in order to build a startup. I think something that has been really interesting to me is that in the lab, you are allowed to not know anything. And especially it's important kind of like to challenge every assumption that you make. Whereas when you're a founder and when you are building a startup, you are expected to have all the questions. So that is...   07:43 kind of one of the major differences that I've seen from the lab and from the startup world. So the ability to ask questions outside of the scientific realm, right? Exactly, yeah. Wow. Another thing that I think is very important is that, in my opinion, not knowing has a lot of value. And in a startup, unlike in a lab, it's better to not know.   08:12 because that is what opens many doors and what pushes the boundaries of what's possible. Wow. So the open sky. Exactly. That's my personal opinion. But yeah, I would say we are in the first box. Thank you. So what has been a major challenge in entrepreneurship? While building licensure into third year, what would you share as a major challenge? Perfect. Yeah. I can tell you   08:41 about the challenge and of course, coming back to your question about the Perfect Team. Yes, sorry. Yeah, I would say to the first question of the major challenge, definitely the landscape, when we started actually scaling with the company, it was when Silicon Valley Bank started to fall. So I remember we were in a meeting, we were in Menlo Park and then suddenly everybody starts texting and then we say, what is going on?   09:10 So we drive in front of the Silicon Valley Bank headquarters in Silicon Valley, and then we start seeing the people there. So I would say we were born out of a time of crisis, and that's what has made us stronger. But the major challenge is definitely the landscape right now. And most importantly, I would say the...   09:40 higher kind of a the higher kind of bar that you are subject to as an entrepreneur because in these times only the best ones thrive. So it's definitely a really fun time to be in and really exciting but also challenging. Thank you. Yeah. So let's go back. Do you have the perfect team to address and thrive in this and these challenging times? I yeah.   10:09 I like to think kind of like out of the box. Yes. As a technical founder and leading a deep tech startup, I see many companies that try to put together teams that are mostly PhDs with a lot of experience, post-docs, former professors, that kind of profiles. But in my view, the biggest challenge of those kinds of teams is that you get, as you advance in life, you get a little bit more   10:39 skeptical of what can be done. So to me the ideal team is similar to what we put together in license which is a combination of a lot of experience with a lot of innovation and a lot of youth. And this goes to a story that I really like from an article that is really   11:09 When one investor funds a company, a really big deep tech company, and the investor as the company, how was the team integrated? And the founder says, okay, like we have the best from this part, the best from this part, the best scientists in the world. And he asked the founder   11:39 And how many of those are under 35? And he says, wait, none. Yeah. And I think that's really interesting because the investor ends up saying, okay, to me, a diverse gen pool needs to have a combination of this kind of experience and also the value of, understanding the value of bringing, you know, people in their 20s that are right side of school that have all the energy in the world. And that don't necessarily know what they are getting into.   12:08 To me, that is the perfect thing. And I can think of a couple of examples of these kinds of things. Actually, you did have some interns during a period of time, right? Postdocs, are they working on the docs from USC or UCLA? Exactly, yeah. Right? Yeah, correct. We had some teammates. That's what I realized, because we have, as teammates, very experienced people.   12:37 And then you see the energy that the interns bring, the perspectives, the desire to push these boundaries. So that's what I love about it. And if you see one company that I really like, that right now is really famous in Los Angeles and that is like thriving, is Rabbit. Before Rabbit started to get hot as it is getting right now once they presented.   13:07 one of their hardware. I was looking at this company in their crunch base profile, and I look at the team and it was really interesting to me that when I saw the team, I saw that their CTO is like 20 years. I think he was part of Carnegie Mellon. He graduated from Carnegie Mellon and he right after became the CTO of this company. And when I saw that, I thought to myself, okay, this is the perfect CTO for this kind of company.   13:37 Yes. So pushing the boundaries, right? Digital natives and representing that generation. That's fascinating. Exactly. And of course, having adult supervision. Right. So a combination. Exactly. Yeah. Right. So you're into the third year. Market wins, they changed in March of last year, as you alluded to with the...   14:06 SVB and First Republic Bank debacle, right? With that background, have you continued to evolve the product market fit because of the market downwinds or what have you done with the product market fit? Yeah, that's a great question. Has it evolved? Yeah. I would say, you know, we need to think in terms of our customers, but also we need to think in terms of our times. Yeah.   14:36 2021, I would say there was a big focus on having the best technology at any cost and more in delaying, for example, revenue, profit, good unit economics. Now that the market has shifted, not only on the investment side, but also on the customer side, the focus is more on...   15:05 the focus of our products is more in generating revenue faster and in building a business that is more real and that can thrive regardless of the market conditions. So yeah, I would say that has been the major change. And in this search for the product market fit, we've realized that it's also important to focus to be super cash efficient.   15:34 to build instead of experimenting with three, four products, it's better to experiment with one product and to testing, but testing with a margin of safety rather than just testing every single perspective. Can you, for the benefit of my listeners that are not deep tech founders, walk us through actually the product in its current state   16:04 how are you creating the ability to identify sites that have better resources, more efficient? So what's the actual tech stack and how are you able to then think about monetizing that? Okay. That is a great question. So we have a product called Alchemist. It's a mineral exploration tool where we integrate remote sensing capabilities and state of the art artificial intelligence algorithms.   16:34 in order to prospect the areas that have potential for critical minerals. So we use remote sensing in a non-invasive way so we can explore for these minerals. So the way we've integrated a platform is in two components. One of them is the platform itself, which is what the customer interacts with. And the other thing, the other component is...   17:02 the what we call the license labs, which is essentially a very sophisticated platform that in the backend allows for the exploration and integration of AI capabilities. So that's the way we've structured it. I think with this advance that has been going on with AI and remote sensing capabilities, I think it's gonna get very exciting in the next few years.   17:32 So we love it. In terms of monetization, definitely. We've thought of some interesting approaches to it. Excellent. So Oscar, in continuation of my question around challenges of an entrepreneur, would you add any challenges as being an immigrant founder? Yeah, Brenda, that's a great question. I do think.   17:59 as an immigrant founder, you get a different perspective and probably you also lived it when you were in Spain. Yes. But one of the major things is figuring out how to build actually a business from scratch in a completely different legal system in a completely different landscape and building a network out of scratch too. Because you come from, in my case, I come from a university that like...   18:28 where I don't have any connections here. And then it's important to learn how to knock doors and how to search for opportunities out of zero. That is one of the major challenges. The other one is culturally, and I've seen it not only as myself, but also from friends that come from Australia, that come from India, that come from Japan.   18:55 that you see that there are some things that you need to be familiar with so that you can make sure to do the things in a diplomatic way. Okay. So I think that's also important. And that's those are the things that people don't tell you about. And the third one is definitely the immigration system, which is, you know, when you're trying to start a company here, you don't even know   19:24 like whether you're going to be able to do it, if you're like allowed, if you can sell something because it can be defined as work. So early in the beginnings of Lisus, that was our major concern. It took us a while to figure it out, to do the green card application, things like that. And once like you solve it, you are like in an even field. But yes, an immigrant, those are things   19:54 a long time and that we have in the back of our mind all the time. I've seen it with many, many founders and it's always a funny to see that we share the same challenges. Thank you for sharing. So, you know, the founders podcast is not solely around deep tech. So I have a lot of listeners that are business owners or founders in non deep tech. So could you describe   20:24 the business model of lysis. You talk about full stack, right? Business model. And I really would like you to get into the weeds to provide some more context of what is the product and how is it scaled and how do you monetize it? Definitely. Yeah, we're product Alchemist. It's a mineral exploration product that we use to search for critical minerals   20:54 And our business model is a full stack play. And essentially this means that we are not using our software and selling it by providing services. Rather we are using it as a tool or as leverage so that we can generate revenue in a faster way. To give you kind of like a better explanation or like a more in depth perspective on the full stack business model.   21:24 I would say when there is a transition or a big opportunity such as the one we are living now, it could be the energy transition where you are living this shift to the electric vehicle. So it could be a long time ago when we transitioned to the World Wide Web or when we started using the cell phone. All of these changes.   21:54 are defined by two waves. You have the first wave where there is a companies that try to solve and to actually serve a market. And there are companies that serve the companies that are trying to serve that market. So full stack means that you are, instead of being a service provider in a market, you're actually the solution provider. In the case, for example, of...   22:23 vehicle electrification should be the most common. There are companies that at the beginning, they started to focus on actually selling vehicles and electrifying. And there were after that, the second wave, a lot of companies that were trying to serve the market of electric vehicles through battery analytics, through efficiency, through different materials, but the big opportunity   22:51 in our view was actually in being the one providing the product. So what we're doing at Lysus is being full stack and becoming a materials company since the beginning. Yes, we have an amazing platform, Alchemist, and we use it to partner strategically with the miners, but we see a lot more value and as a company in being the actual solver of the problem and being the actual supplier of   23:20 the materials rather than just serving miners and serving companies that are focused on providing materials for batteries. That's why we think it's really an interesting business model and most importantly because full-stack businesses have proven in history to provide much better opportunities for revenue. Let's say   23:48 Some examples are Flexport, for example, SpaceX, companies that since the beginning, they tried to solve the problem rather than just being a service provider. Excellent. I also am thinking of Atlassian. They created quite a bit of work tools for developers of code.   24:17 Jira is one of their products, but they built, right? So Last scene is one of the companies, it's out of Australia, funny enough, created a lot of enterprise value early on and their tools are pervasive in the engineering teams that are building code today. So that's the analogy that I found while working with Lysis trying to get out of clean tech and looking at other.   24:44 There's similar analog businesses. Yeah, no, Atlassian is a great example. And we use it on a daily basis. I bet. We use all the tools, and it's amazing. So that kind of thing we have. Right. And we just had a great segue into clean tech. So Lysis is full-stack working in one of the deep tech sectors or verticals of clean tech. What are some of the things you're   25:14 clean tech market right now? Yeah, that's a great question. You know, the most interesting to me, of course, is critical minerals. It's probably the most boring, but it's also the one where we're gonna see the most exciting changes and advances. Some other things that are interesting are new materials. That is really interesting to me, because I think there is gonna be big opportunities in new materials and in...   25:44 in nature-based solutions. That's also something that's very... Right, synthetic. So within the biotech applied with nature. Exactly. And yeah, and I've been exposed also just to new techniques applied to solar panels that increase the efficiency. So there's always, it's all about efficiency, right? To compete with...   26:12 Oil and gas, right, in terms of the parity or gas lead for your car, right, electric vehicles. Yeah, no, I agree. Yeah. And something that is really interesting, too, I think that in the future, like, I envision a world where materials are going to be produced differently. And we are going to leverage nature to produce these materials. So I've seen, for example, very interesting companies that are using nature to produce   26:42 to separate minerals, for example, or that are using it to produce different type of materials, modifying it, et cetera. Of course it has its risk, but I think it's really interesting to see organic-based solutions. So that is another one that is interesting. And the other ones are in energy. I don't think that our energy system is gonna change drastically, but I do think   27:12 there is gonna be a lot of changes in how we use energy, how we store energy, yeah, what is the way in which we use energy. Those are some things that are amazing to me and where I see a lot of changes. And yeah, probably we're gonna see very interesting models for carbon capture.   27:41 Dequestration. Exactly, yeah. And technologies to solve the problem in the point source. I am not that much excited about the kind of like carbon credits, things like that. But I am very much about the technological approaches to it and also innovations in transportation. That's also really exciting. It's the biggest sector in energy consumption.   28:09 Actually, transportation, people don't think that. I think it's right. I'm sorry, in the emission of CO2. Correct, yeah. And GSD is transportation. Right. And what about, this is actually a nice little conversation about innovation and clean tech. But what do you think about the space that Lysis is competing in? Right.   28:37 efficiency and better site identification where the rare earth metals or the critical minerals are. You've got other competitors that are looking at it in a different way. Can you talk about how the identification of rare earth metals is evolving across the world?   29:06 Yeah, that's a great question. It's definitely an interesting field and one that is very small, because of course, it has a lot of barriers to entry. So when people realize that it's not as easy as they thought, they leave it. So yeah, definitely all the founders that are working in this sector have heard of each other or know each other. So that is fun. I would say.   29:35 in the part of critical minerals, in the market of critical minerals, it's a really old school field. It's really old school. You're using tools that you have been using for a hundred years and they've been working really well. So the big opportunities are in bringing new type of sensing and incorporating it in the sector of mineral exploration. But also I think it's very important to continue using some of the things that   30:04 have been done really well and help them optimize their operations. I think the major innovation in the sector is not gonna be in the technology, but on the business model. And I think, and I've seen it like with all the companies, all the funds, everyone is trying to figure out the right business model and go beyond just the project financing and being a fintech company, which in reality, all the mining companies are fintech companies.   30:33 into being more of a company that can produce better returns in an interesting way. So yeah, I think it's one of the most exciting fields to be in because there is going to be so much innovation, but also innovation is not going to come in the way we think it's going to come.   31:03 you to provide my listeners how they may contact you personally, right? Oscar is CEO and founder of Lysis as well as your company contact details. How's it best to learn more about Lysis, Alchemist and yourself? Yeah, through the website, you can in the website, you can get into contact us. So what is the website? The website is www.   31:33 Lizusenergy.com. And then right there, you can request to contact us and then you're going to get access to our calendar. And as quick as that, you can book a time with us to chat. And then also, you know, we're emailing, which is partnerships at Lisusenergy.com. There we can also chat. And if you have any ideas, careers, or any interesting perspective, we would love to hear from you.   32:02 Excellent. And I love to do a round of questions to each of my guests that kind of mirrors what I do at Next Act Advisors. I talk about sustainable businesses, resilience, and purpose-driven organizations. Not one guest has the same definition, and it's fascinating to do a little round of questions here. What does resilience mean to you, Oscar?   32:34 Yeah. Resilient to me means a, I see it kind of like as a synonym of perseverance, which is even if you fall, you can fall a hundred times and you stand up and continue going. That's what resilience means to me, being able to get hit and keep going. And it's very necessary in the early stages of a. Possibly. I would say it's possibly much more necessary than.   33:04 having a good academic background or having experience as an entrepreneur. What I've seen is that the best entrepreneurs are the ones who are resilient and who keep going no matter what. Excellent. Perseverance. Purpose-driven enterprise. You know, the title that we chose for this podcast episode is a sustainable business model in a sustainable market. What is purpose-driven enterprise for you?   33:35 To me, purpose has to be holistic rather than just focusing on one specific thing. I think it's important to think holistically and incorporate different attributes to pursue the right purpose. So I would say a purpose-driven enterprise is a company that has a very clear north star and that has different paths to go and follow that north star.   34:04 That's the way I would define it. What would be licenses Northstar? I would say over Northstar is sustainability and not environmentalism. So the way we see it is that there is kind of like certain currents where companies tend to try to be only environmentalist without incorporating other aspects. Got it. So to us...   34:34 that would be the north star, like being sustainable rather than being just environmentally friendly. Excellent. And finally, sustainable growth, not to be confused with sustainability. What is sustainable growth? So what is that growth curve right for you? How to consistently grow a business? Yeah, that's a great question. Sustainable growth means, in my view,   35:03 considering the environmental aspects, but also considering a sustainable business model that can self-fund itself. So the way I would see it is, okay, you're gonna build a company of X. And if you're gonna build this company only thinking in terms of environmentalism, you are doing it not in the right way, because you also need to consider how you're gonna fund.   35:32 those, that purpose and that mission. So sustainable growth means constantly, constantly checking to make sure that you are doing it well, but also creating systems so that you can fund that mission. Very good. That's very holistic, as you as you suggested. Exactly. Final question. Did you have fun in the sandbox today, Oscar?   36:00 Definitely. Yeah. It's the first time that I do a podcast. And I love it. Really interesting. And there are many things that you don't get to share on a day to day basis. So amazing opportunity kind of like to talk about some of the things that we believe in. Thank you. I want to let my listeners know that we will be providing   36:29 the show notes and the release of this podcast during the month of February. And more importantly, the article you've mentioned about how to build a perfect team, right? And your eyes will reference that in the show notes, as well as how to contact the founder of Lysis Energy. And yeah, so thank you very much for joining me and the founders sandbox.   36:59 along with Oscar Negra of Lysis. This episode will drop in February and you will always find the podcast available on all major platforms, Spotify, Apple, and wherever you get your podcasts. So thank you for listening in and see you next month. Thank you, bye.

He's back! The wonderful Richard Swatton is on the podcast to discuss dreams. We cover a lot in a short period, so we decided to make this a series on dreams. Related episodes top follow so watch this space! For the opportunity to have your chart analyzed by Richard in future episodes, become a patron! (links below) What did you think of today's episode? Share your thoughts/dreams/experiences in the comments! 00:00:03 Intro 00:02:00 Archetypes in Dreams 00:05:35 The subterranean mind 00:08:13 Astral landscape/Dreams during a Pluto transit 00:10:17 Astral (different types of dreaming) 00:13:20 Lucid (different types of dreaming) 00:18:29 Etheric (different types of dreaming) 00:21:39 Collective Unconscious & Transpersonal planets 00:23:30 Neptune synching with substance 00:28:13 Pluto in dreams (my exploration) 00:39:29 Messages from dreams to reality 00:46:03 Who is the conscious party? 00:48:27 Dreaming of loved ones, passed 00:53:30 Jung's General structure of dreams Exposition / Peripetia / Crisis / Lysis 00:55:51 Who is the ultimate observer? 01:01:23 Krishna Murti 01:02:06 Marie-Louise von Franz 01:05:35 Key planetary players for dream work 01:17:50 The Sopranos 01:20:11 Spoiler Alert! 01:21:50 Spoiler over/Pulled into our future 01:33:51 Working with Dreams/Patrons LINKS Watch this episode https://youtu.be/eQzs9IbgnSs The dictionary of symbols  https://www.amazon.co.uk/Complete-Dictionary-Symbols-Myth-Literature/dp/1844830136 Jungs 4 stages of a typical dream https://studylib.net/doc/25194391/ Marie-Louise von Franz - The Way of the Dream https://www.youtube.com/watch?v=2MZ0G4PEe2g Krishna Murti https://en.wikipedia.org/wiki/Jiddu_Krishnamurti Richard's Course for the LSA: Worlds Beyond Ego https://www.londonschoolofastrology.com/courses/worlds WTF is Astrology? (Previous Episode) https://youtu.be/dNqDsIMrrxM The Astrology Squad https://astrologysquad.com/ From Symbol to Substance: Training the Astrological Intuition by Richard Swatton https://www.amazon.co.uk/Symbol-Substance-Training-Astrological-Intuition/dp/1516984447 The Horary Process: A Magical Approach to an Ancient Art contact: info@flareUK.com If you have any dreams you want to contribute for discussion (and potential chart analysis) please submit your details here: https://www.patreon.com/posts/star-in-dream-93236951?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link Email me if you would like a reading with Richard: stelliumastro@gmail.com

It is my honor to be joined on this episode by Olympia at Fertilysis to discuss all things unexplained infertility, reproductive immunology, microbiome and more.If you or someone you know is experiencing unexplained infertility or recurring loss, this episode is for you.A little bit about Fertilysis:FERTILYSIS - rooted at the words “FERTILE” and the Greek word “LYSIS”, which translates into “solution to a problem”…the problem consists of known and emerging fertility issues while the solution ~ lysis represents our new innovative testing approaches!The mission in FERTILYSIS is to provide a systematic, comprehensive, etiological investigation of infertility with breakthrough full-spectrum testing solutions , which can be performed safely at home, coupled with clinical consultation resulting in pregnancy and the delivery of healthy babies.Connect with Fertilysis: Website:https://www.fertilysis.comInstagram:https://www.instagram.com/fertilysisSponsors: Toxic Free CleaningUse code BROOKE30 to save 30%https://trulyfreehome.comOrganic Herbal Remedies Use Code BROOKE10 to save 10%https://earthley.com/ref/brookebacci/Clinical Collagen  - Botox  in a bottleSave $10 with link or use code 4842132https://modere.co/3prgdUs

Nicolas :  En panel, nous avons reçu deux réalisatrices produites par l'ONF, dont les films sont présentés aux RIDM 2023 l Rencontres internationales du documentaires de Montréal : Romane Garant-Chartrand, avec « Après-Coups », et Habibata Ouarme, avec « Koromousso (Grande soeur) ». À attraper au festival entre les 21 et 26 novembre. Sinon dès le 25 novembre sur ONF.ca pour Koromousso. Si possible, je partagerais leurs bandes-annonces sur IG.   Théo:  En studio avec nous pour la première fois avec nous Théo qui nous propose une entrevue sur la première mondiale de la composition intitulée Lysis, produite par l'Orchestre de l'Univestié de Montréal à la maison symphonique qui c'est déroulée le 12 novembre. Nathaniel:  Cette semaine, une phrase m'a bondi dessus et m'a garroché dans un tourbillon de réflexions et de souvenirs qui m'ont déposé devant l'importance de la culture. Comme la dernière fois, j'entremêle ma plume de celle des sages conteurs, mais pas de philo-fable aujourd'hui! Je l'ai plutôt repêchée de mes souvenirs mais l'ai retrouvé en tapant des mots clés. Je vous épargne la recherche, une version de l'histoire est ici: https://www.evolution-101.com/le-vieux-sage-et-le-marchand/ Au plaisir de vous revoir bientôt, Prenez soin de vous! -Nathaniel Bronner Mireille:  @tdormtl @mformontreal @super_plage @hawa.b.music @gazolinemusique @pony_shopmtl  

Arthrofibrosis (AF) after anterior cruciate ligament reconstruction (ACLR) remains a challenge. There is a paucity of data on arthroscopic interventions for AF after ACLR.   In conclusion, an arthroscopic intervention for AF after ACLR successfully improved knee ROM and pain. Patients who underwent either early or late surgery obtained satisfactory motion and function, although improved PROs were observed when the intervention occurred within 3 months of the primary procedure.     Click here to read the article.

Emails: liamconnerly@gmail.com latininlaymans@gmail.com Anemia: Etymology: Greek "an-" (without) + "-haima" (blood) Origin: Greek Definition: A condition characterized by a deficiency of red blood cells or hemoglobin, leading to reduced oxygen-carrying capacity. Leukemia: Etymology: Greek "leukos" (white) + "-haima" (blood) Origin: Greek Definition: A group of blood cancers characterized by the abnormal production of white blood cells. Hypoglycemia: Etymology: Greek "hypo-" (under) + "glykys" (sweet) + "-haima" (blood) Origin: Greek Definition: A condition marked by abnormally low levels of glucose (sugar) in the blood. Hyperglycemia: Etymology: Greek "hyper-" (over) + "glykys" (sweet) + "-haima" (blood) Origin: Greek Definition: A condition characterized by abnormally high levels of glucose (sugar) in the blood. Uremia: Etymology: Greek "ouron" (urine) + "-haima" (blood) Origin: Greek Definition: A toxic condition resulting from the accumulation of waste products in the blood, typically due to kidney dysfunction. Polycythemia: Etymology: Greek "polys" (many) + "-kutos" (cell) + "-haima" (blood) Origin: Greek Definition: An increase in the number of red blood cells in the blood, often leading to thicker blood. Bacteremia: Etymology: Greek "bakterion" (small rod or staff, referring to bacteria) + "-haima" (blood) Origin: Greek Definition: The presence of bacteria in the bloodstream, often indicating infection. Septicemia: Etymology: Greek "septikos" (putrefying) + "-haima" (blood) Origin: Greek Definition: A serious bloodstream infection usually caused by bacteria and their toxins. Hematemia: Etymology: Greek "hematos" (bloody) + "-haima" (blood) Origin: Greek Definition: The presence of blood in vomit. Hydrolysis: Etymology: Greek "hydro" (water) + "-lysis" (decomposition) Origin: Greek Definition: A chemical reaction in which water is used to break down a compound into its constituent parts. Electrolysis: Etymology: Greek "electro" (electricity) + "-lysis" (decomposition) Origin: Greek Definition: The process of using an electric current to drive a chemical reaction, often used for hair removal and metal purification. Autolysis: Etymology: Greek "auto" (self) + "-lysis" (decomposition) Origin: Greek Definition: The self-digestion or breakdown of cells by their own enzymes after death. Proteolysis: Etymology: Greek "proteo" (protein) + "-lysis" (decomposition) Origin: Greek Definition: The enzymatic breakdown of proteins into smaller peptides or amino acids. Thrombolysis: Etymology: Greek "thrombos" (clot) + "-lysis" (decomposition) Origin: Greek Definition: The process of dissolving a blood clot using medication or enzymes. Photolysis: Etymology: Greek "photo" (light) + "-lysis" (decomposition) Origin: Greek Definition: The breakdown of chemical compounds through the action of light. Osmolysis: Etymology: Greek "osmo" (push) + "-lysis" (decomposition) Origin: Greek Definition: The rupture or dissolution of cells due to changes in osmotic pressure. Cytolysis: Etymology: Greek "cyto" (cell) + "-lysis" (decomposition) Origin: Greek Definition: The destruction or bursting of cells, often due to osmotic imbalances. Fibrinolysis: Etymology: Greek "fibrin" (a protein involved in blood clotting) + "-lysis" (decomposition) Origin: Greek Definition: The process of breaking down fibrin clots in the bloodstream. Necrolysis: Etymology: Greek "nekros" (dead) + "-lysis" (decomposition) Origin: Greek Definition: The decomposition or disintegration of dead tissue. --- Support this podcast: https://podcasters.spotify.com/pod/show/liam-connerly/support

Bonjour et bienvenue dans ce premier épisode du podcast APHRODISART. Je vous propose aujourd'hui de traiter un sujet antique : la sexualité dans la Grèce antique et plus particulièrement à Athènes.  Orgie, homosexualité, banquet, on entend un peu de tout mais qu'est-ce qui est vrai ?  Si vous êtes curieux et intrigué, je vous invite à écouter cet épisode. Instagram et Tiktok : Aphrodisart_ Quelques notions :  L'histoire de la Grèce antique s'étend sur 1000 ans environ. C'est-à-dire du VIIIe av. J.-C jusqu'au christianisme. Les historiens ont aujourd'hui découpé en 3 tranches chronologiques cette époque : on a dans un premier temps l'époque Archaïque, l'époque classique, du IVe/ Ve soit de 500 à 336 avant notre ère. Cette époque est réputée pour être apogée du monde grec et l'époque Hellénistique qui va du Ier siècle avant notre ère jusqu'à la mort de Cléopâtre. Les vases à figures noires réalisés entre 620 – 480, soit l'époque Archaïque.  Les vases à figures rouges exécuté entre 530 – 320 soit l'époque Classique. Nu se dit gymnos en grec. qymnastikè (gymnastique).  Les Lacédémoniens et les Spartiates  Thucydide = homme politique, stratège et historien athénien, né vers 460 av. J.-C. dans le dème d'Halimonte  érastes et éromènes = l'amant et l'aimé Les hétaïres = femmes étrangères libres. Ce sont donc des courtisanes autonomes et qui sont souvent des musiciennes ou des danseuses.  Coupe du Peintre de Brygos, qui date de 490-480  et exposé au British Museum SOURCE : - S. BOEHRINGER, « En Grèce », dans S. STEINBERG (éd.), Une histoire des sexualités, Paris, PUF, 2018, p. 33-64.  - M. SARTRE, « L'homosexualité dans la Grèce ancienne », dans La Grèce ancienne, Paris, Points-Seuil n° H87, 1986, p. 189-205.  - M. SARTRE, « Virilités grecques », dans G. VIGARELLO (dir.), Histoire de la virilité, 1. L'invention de la virilité, de l'Antiquité aux Lumières, Paris, 2011, p. 19-65. - G. SISSA, Sexe et sensualité : la culture érotique des Anciens, Paris, 2011.  - Cl. MOSSE, « Nééra, la courtisane », dans N. LORAUX (dir.), La Grèce au féminin, Paris, 2003, p. 217-246 - Mes cours à Sorbonne Université "littérature et archéologie Grecque" - P.HAMON L'ouvrage ou vous pouvez retrouver le témoignage de Socrate : "PLATON, Lysis,pages 206 e- 209 e (trad. L. Brisson, Flammarion)” Crédits musiques : Gregor Quendel - Cinematic Celesta Trailer Score.wav  - Freesound Aaron Paul Low - “ Thought Patterns” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/aaron-paul-low/thought-patterns License code: GVQ7WNAKOSHKMMRX Tobias Voigt - “ Pieces of light” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/tobias-voigt/pieces-of-light License code: KHVNDLDRAOK9HXUG All Good Folks - “A seafaring Adventure” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/all-good-folks/a-seafaring-adventure License code: AL0G7BFKYWDVFGMY Alex Besss - “The last Dragon” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/alex-besss/the-last-dragon License code: LMIFNOSFSRZS9YEE All Good Folks - “ Magnificens” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/all-good-folks/magnificent License code: TBOWWNFQMH7PMPN9 Monument Music - “ Betrayal” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/monument-music/betrayal License code: UUKWRNHI3EMHIDMD Jonny Easton - “ Banquet of Squires” - Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/jonny-easton/banquet-of-squires License code: A1NTZGOJ0SSPGKZX   Bonne écoute - APHRODISART 

Magnus och Svempa åkte till Krylbo Mangel och intervjuade Lysis, Maniak, Twin Pigs och Defleshed i varierande grad av stök och kaos. Dessa band utgjorde tillsammans med Xion, Hymans, The Sensitives, Asocial och Woflbrigade utgjorde årets lineup på årets upplaga. Vi pratar dessutom med Emil Lantz som är mannen som startat alltihop och som verkligen brinner för en levande undergroundscen i Dalarna med omnejd.  Bilder från kvällen hittar ni här Stort tack till Emil och alla trevliga människor vi stötte ihop med den 1 juli. Vi ses nästa år igen! 

I keď sa hovorí, že zlaté dno má remeslo, verím, že o priateľstve, tom skutočnom priateľstve, by sme vedeli povedať niečo podobné. Mať priateľa nie je len výhodné, ale dobré. Robí nás to lepších, a súčasnej aj našu spriatelenú dušu. Čo to ale skutočné priateľstvo je? A je naozaj potrebné pre šťastný život, keďže priateľ je stále len smrteľník ako my a jeho smrť môže viac ublížiť ako pomôcť? O týchto otázkach a celkovej filozofii priateľstva už o chvíľu.----more----     Súvisiace dávky:   PD#287: Filozofia lásky, http://bit.ly/davka287 PD#283: Platónov dialóg Republika, http://bit.ly/davka283 PD#117: Priateľstvo ako spravodlivosť, http://bit.ly/davka117     Použitá a odporúčaná literatúra:   Plato, Lysis (http://classics.mit.edu/Plato/lysis.html) Reeve, Plato on Friendship and Eros (Stanford Encyclopedia of Philosophy) Helm, (Stanford Encyclopedia of Philosophy) Helm, Friendship (Stanford Encyclopedia of Philosophy) In Our Time, Friendship (BBC) Pangle, Aristotle and the Philosophy of Friendship (Cambridge, 2003) Jeske, The Routledge Handbook of Philosophy of Friendship (Routledge, 2023) Moseley, Philosophy of Love (Internet Encyclopedia of Philosophy)   ***   Baví ťa s nami rozmýšľať? Získaj extra obsah cez Patreon (https://bit.ly/PDtreon), alebo nás podpor ľubovoľným darom (https://bit.ly/PDdar)

Most blood cancer patients can experience side effects from their cancer diagnosis, or its treatments. In certain blood cancers, an… The post Tumor Lysis Syndrome: What Patients Need to Know first appeared on The Bloodline with LLS.

Most blood cancer patients can experience side effects from their cancer diagnosis, or its treatments. In certain blood cancers, an… The post Tumor Lysis Syndrome: What Patients Need to Know appeared first on The Bloodline with LLS.

Lysis

After another long break, today we finally finish discussing Plato's dialogue on friendship, the Lysis. In this episode, we cover Socrates' refutation of last episode's conclusion, the role of desire in friendship, whether or not evil is the cause of friendship, and the fact that friendship is so hard to give an account of despite the fact that we all seem to know we have friends.

In this Plato dialogue - Socrates engages Lysis and Menexenus trying to explore the question of what friendship truly is. Thank you for listening.You can contact us @: ericknga7@gmail.com

Ashlie Crewe, a Physical Therapist with a Psychology degree, embarks on a journey to help patients manage their chronic pain using neuroscience, only to find her own trial by fire as she discovers a unique way to challenge a patient's overprotective nervous system. "The beautiful thing, good and bad, is that physical therapists, we're not allowed to prescribe medicine in the United States. So I think one of the cool things about my job then is we're really taught to work with the human body, and we're not allowed to order imaging, we're not allowed to prescribe medications.” Ashlie Crewe is a Pelvic Health physical therapist and teacher/mentor to Pelvic Health physical therapists across the United States. She has a passion for neuroscience, psychology, and Pelvic Health, making her an expert in persistent pelvic pain. Ashlie Crewe found her true calling when she attended her first pelvic health class after physical therapy school. The class blew her mind and she knew the neuroscience of pain was the way to help patients with persistent pelvic pain. She quickly developed her skills and started to understand how to apply the neuroscience of pain to her practice. She creates a space with her patients to make them feel safe and trusts them to choose their own treatment path. She assesses their tissues, looking for any signs of adherence, and then checks their nervous system to see how it responds. Through this practice, she helps to rewrite the painful stories her patients have been told and shows them that physical therapy can provide them with lasting relief. In this episode, you will learn the following: 1. How does physical therapy help treat chronic pain and persistent pain conditions? 2. How does the relationship with a therapist impact a patient's improvement? 3. How can physical therapists use neuroscience to assess and treat pelvic pain? Resources: International Pelvic Pain Society - https://www.pelvicpain.org/ Drayer Physical Therapy for northeast USA - https://drayer.urpt.com/ Upstream Rehabilitation for across USA - https://urpt.com/ Other episodes you'll enjoy: Lichen Sclerosus and Overactive Pelvic Floor - https://youtu.be/mxQjC3jEoYg Dr. Rachel Rubin: Unlocking Clitoral Fusing Through Non-surgical Lysis - https://youtu.be/F5KO5LGXRx0 Vulva Checks for Lichen Sclerosus: Everything You Need To Know - https://youtu.be/E9fnXDh5up4 Connect with me: Instagram: https://www.instagram.com/lichensclerosuspodcast/ YouTube: https://www.youtube.com/channel/UCQXU-nhfnn-nScR_5VyUdCQ Website: https://lssupportnetwork.org/ If this episode was helpful to you, we'd love your support so we can continue providing important education like this. Make a donation today at https://lssupportnetwork.org/donate. Loved this episode? Leave us a review and rating here: https://lovethepodcast.com/lspodcast

In this podcast episode, Dr. Rachel Rubin sheds light on the startling truth that 23% of all women suffer from Clitoral Adhesions and how her innovative stretching procedure has resulted in a 76% decrease in pain and a 64% increase in orgasm rate for these women. "We have so much work to do because no one taught your doctor how to examine a clitoris. No one. They never learned. They feel like it's not their space and it's not their place, and they feel weird of, what am I looking for? No one ever taught me how to do this." Dr. Rachel Rubin is a urologist and specialist in sexual medicine outside of DC. She has a fellowship in sexual medicine and sees all genders, specializing in pelvic pain, vestibulodynia, hormone issues, and Lichen Sclerosus. Dr. Rachel Rubin was shocked to discover that 23% of all women have some degree of clitoral adhesions. She developed a non-surgical lysis procedure, which combined topical hormones and manual stretching to break up the tissue. Through her research, she found that this method had a 76% decrease in pain and 71% increase in sexual satisfaction. Furthermore, 64% of the women experienced improved orgasmic ability, with six of the women in the study achieving orgasm for the first time. Dr. Rubin was delighted to have found such an effective, non-invasive treatment for clitoral adhesions. In this episode, you will learn the following: 1. Discover why 23% of all women have some degree of clitoral adhesions and what symptoms this can cause. 2. Learn about a new procedure that can help 76% of women reduce pain, improve satisfaction with sex, increase sexual arousal, and even help 64% of women achieve orgasm for the first time. 3. Uncover the secrets to treating lichen sclerosus optimally before any procedure is done, including what hormones and topical treatments can be used. Resources: Check out all the ways Lichen Sclerosus Support Network can help you at https://lssupportnetwork.org. Read Dr. Rubin's blog on the study of non-surgical lysis of clitoral adhesions at https://www.rachelrubinmd.com/post/new-research-on-clitoral-adhesions Connect with Dr. Rubin Website - https://www.rachelrubinmd.com/ Instagram - https://www.instagram.com/drrachelrubin Twitter - https://twitter.com/drrachelrubin Facebook - https://www.facebook.com/DrRachelRubin/ Linked In - https://www.linkedin.com/in/rachel-rubin-7433b0134/ Learn more about anatomical changes caused by Lichen Sclerosus in our blog - https://lssupportnetwork.org/architectural-changes-lichen-sclerosus/ Connect with us: Instagram: https://www.instagram.com/lichensclerosussupportnetwork/ YouTube: https://www.youtube.com/channel/@lichensclerosussupportnetwork Website: https://lssupportnetwork.org/ Loved this episode? Leave us a review and rating here:  https://lovethepodcast.com/lspodcast  

Drs Short and Reagan discuss risk factors that can contribute to patients' likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.

We're back! After a long break, today we continue to discuss Plato's dialogue on friendship, the Lysis. In this episode, we follow Socrates's dissection of the love relation between two friends, determine whether birds of a feather flock together or opposites attract, and contemplate the role that friends play in our endeavors towards being good. Don't forget to email us at philosophicalpodcast@gmail.com if you have any requests for a review or any feedback!

On this week's episode, we begin discussing Plato's dialogue on friendship, the Lysis. In particular, we talk about same-sex relationships in ancient Greece, whether parents' love for their children consists in wanting them to be happy, and how learning often requires acknowledging that we might not know what we think we do. Next week, we'll finish the Lysis by focusing on the question: What is a friend? Don't forget to email us at philosphicalpodcast@gmail.com with any thoughts, feedback or books you want us to discuss in the future! 

In this episode, we invite Dr. Amir Ali, PharmD, BCOP to discuss with us the pathophysiology, risk factors, prevention, and treatment clinical pearls of tumor lysis syndrome TLS). Key Concepts TLS is caused by rapid cell death of cancerous cells that results in intracellular contents “spilling” into the blood – this leads to high serum uric acid, high serum potassium, high serum phosphate, and LOW calcium. These laboratory abnormalities cause acute kidney injury (via crystal formation in the kidney), arrhythmias (from hyperkalemia), and seizures (from high phosphate and low calcium). Patients at highest risk for TLS are those with hematologic malignancies (lymphomas and leukemias), especially if WBC or LDH labs are very high. Prevention is the Key! The primary prevention approach for TLS is hydration, allopurinol, and sometimes a low dose of rasburicase. The treatment of TLS involves more aggressive hydration and rasburicase. References Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review [published correction appears in J Clin Oncol. 2010 Feb 1;28(4):708]. J Clin Oncol. 2008;26(16):2767-2778. doi:10.1200/JCO.2007.15.0177 Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578-586. doi:10.1111/j.1365-2141.2010.08143.x Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661-671. doi:10.1111/bjh.13403

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

En este episodio estaremos hablando de tumors markers asociados al cancer. También sobre leucemia: ALL, AML, CLL and CML. Además de la complicación Tumor Lysis syndrome. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

CME credits: 0.50 Valid until: 06-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-whos-at-risk-preventing-and-managing-tumor-lysis-syndrome-and-neutropenia-in-cll/13144/ Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes. A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

CME credits: 0.50 Valid until: 06-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-whos-at-risk-preventing-and-managing-tumor-lysis-syndrome-and-neutropenia-in-cll/13144/ Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes. A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

In this episode we take you through the approach to a patient with tumour lysis syndrome. We explain the Cairo-Bishop scoring, and cover the treatment of all facets of the syndrome.